{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:14:28Z","timestamp":1758593668823,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.01.007","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T04:48:57Z","timestamp":1238647737000},"page":"S5-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S3","title":["Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia"],"prefix":"10.1053","volume":"46","author":[{"given":"Carmen","family":"Fava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.01.007_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V17.1.1.1","article-title":"Busulfan in the treatment of chronic myelocytic leukemia","volume":"17","author":"Haut","year":"1961","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib3","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia","volume":"29","author":"Kennedy","year":"1972","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib4","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.10931","article-title":"Autologous stem cell transplantation for patients with chronic myeloid leukemia","volume":"95","author":"Koziner","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM199303043280901","article-title":"Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program","volume":"328","author":"Kernan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","article-title":"Clinical investigation of human alpha interferon in chronic myelogenous leukemia","volume":"69","author":"Talpaz","year":"1987","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(03)70040-7","article-title":"Interferon-alfa for chronic myeloid leukemia","volume":"40","author":"Baccarani","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"issue":"Suppl 15","key":"10.1053\/j.seminhematol.2009.01.007_bib12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp070482","article-title":"Targeted chronic myeloid leukemia therapy: seeking a cure","volume":"64","author":"Fausel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00001622-200403000-00002","article-title":"Treatment options for chronic myeloid leukemia: Imatinib versus interferon versus allogeneic transplant","volume":"16","author":"Angstreich","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib15","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"year":"2009","series-title":"NCCN: clinical practice guidelines in oncology","key":"10.1053\/j.seminhematol.2009.01.007_bib16"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib17","first-page":"100","article-title":"Inhibition of the ABL protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib21","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib22","doi-asserted-by":"crossref","first-page":"15a","DOI":"10.1182\/blood.V110.11.25.25","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib24","first-page":"18","article-title":"Significant survival improvement with a combination of interferon alpha2b (IFN) and cytarabine (ara-C) in chronic myeloid leukemia (CML)","author":"Guilhot","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib25","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib27","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib29","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib30","doi-asserted-by":"crossref","first-page":"609a","DOI":"10.1182\/blood.V108.11.2149.2149","article-title":"Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT trial study group","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/jco.2006.24.18_suppl.6535","article-title":"High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up","volume":"24","author":"Aoki","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib32","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"author":"Hitt","key":"10.1053\/j.seminhematol.2009.01.007_bib33"},{"year":"2008","series-title":"Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia","key":"10.1053\/j.seminhematol.2009.01.007_bib34"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"A prospective study of imatinib 400 mg vs 800 mg as a front-line therapy in Sokal high risk Ph+ chronic myeloid leukemia patients","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib36","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib38","first-page":"48","article-title":"Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)","volume":"93","author":"Cortes","year":"2008","journal-title":"Hematologica"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib39","doi-asserted-by":"crossref","first-page":"376s","DOI":"10.1200\/jco.2008.26.15_suppl.7016","article-title":"Efficacy of nilotinib (AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)","volume":"26","author":"Cortes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib40","doi-asserted-by":"crossref","first-page":"385s","DOI":"10.1200\/jco.2008.26.15_suppl.7054","article-title":"Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML working party","volume":"26","author":"Rosti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib41","first-page":"161","article-title":"Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase 2 trial of the GIMEMA CML working party","volume":"93","author":"Rosti","year":"2008","journal-title":"Hematologica"},{"key":"10.1053\/j.seminhematol.2009.01.007_bib42","doi-asserted-by":"crossref","first-page":"375s","DOI":"10.1200\/jco.2008.26.15_suppl.7013","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"26","author":"Borthakur","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:21Z","timestamp":1758521961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":42,"alternative-id":["S0037196309000183"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}